call Toll Free (US/Canada) : +1 866 658 6826 | call +1 425 320 4776 | call (UK) : +44 1865 60 0662 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Glaucoma Therapeutics Market Bwc19434
Inquire Before Buying Request for Sample

Glaucoma Therapeutics Market Bwc19434

Home Healthcare And Pharmaceutical Glaucoma Therapeutics Market Bwc19434

SPECIAL OFFER : 25% Super Discount For All !

Glaucoma Therapeutics Market, By Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Combination Drugs), By Disease Indication (Open Angle Glaucoma, Angle Closure Glaucoma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26

  • Published Date: March 2020
  • Report ID: BWC19434
  • Available Format: PDF
  • Page: 180

Report Overview

Global Glaucoma Therapeutics Market Forecast and Trends

The global Glaucoma Therapeutics market has reached 6272.89 million in 2019 and estimated to reach USD 7658.98 million in 2026 and anticipated to grow by CAGR of 2.96% during the forecast period 2020-2026. Increasing physician's preference to laser surgery for glaucoma care would accelerate the growth of the demand for glaucoma therapy over the forecast period. Improved diagnostic tools in the ophthalmic industry and a growing pool of geriatric population worldwide contribute considerably to the growth of the glaucoma therapeutics market. Furthermore, the late-stage pipeline therapy provides promise for glaucoma care, while the launch of novel therapeutic approaches by key players on the global market is expected to fuel the growth of the glaucoma therapy industry over the 2020-2026 forecast period. The recent development in intraocular imaging technology is expected to offer lucrative market prospects in the clinical sector for the glaucoma therapeutics market in upcoming years.

Global Glaucoma Therapeutics Market: Overview

Glaucoma is the eye disease that damages the optics of the patient's eye nerve. The extra fluid forming up in the front of the eye causes damage to the optics of the eye nerve. Glaucoma is a two-type, primary open-angle glaucoma & angle-closure glaucoma, often referred to as narrow-angle glaucoma. The most common type of glaucoma is Open-Angle glaucoma. Primary glaucoma eventually develops when the eye does not absorb the fluids. This results in pressure building on the optics of eye nerves. Open glaucoma does not induce any alteration in the vision of the eye, and it is also painless. Closed-angle glaucoma occurs very close to the drainage angle, which results in a blockage of the eyesight drainage angle. That is a form of glaucoma that is very acute.  This type of glaucoma can affect the patient's vision and can lead to severe eye and headache pain.  Glaucoma is generally treated with eye drops, pills, conventional surgery, laser surgery, and sometimes these approaches combined. Regular drug consumption, as prescribed by the doctor, is essential for proper glaucoma treatment.  Glaucoma drugs have much fewer chances of effects, which have increased its adoption on the global market.

Growth Drivers

The increasing prevalence rate of glaucoma

The shift in people's lifestyle has led to an increase in glaucoma prevalence globally. Increasing glaucoma prevalence is the primary factor driving the development of the global demand for glaucoma therapy. Glaucoma is more common in people older than 60 years. The rising geriatric population believed that the world is also responsible for the robust growth of the demand for glaucoma therapy over the forecast period.

Improving Diagnostic techniques coupled with rising government support

Improving diagnostic techniques, developing new drug delivery systems, and introducing new drug combinations combined with increasing glaucoma patients are key factors driving the growth of the therapeutic market for glaucoma worldwide. Increased government support and healthcare companies ' initiatives in raising awareness about glaucoma treatment also support market growth.

Restraint

High Cost & low availability of skilled professionals for laser surgery

Lack of availability of specialized laser surgery professionals in developing economies will also hamper the growth of the market for glaucoma therapy. Besides, high costs associated with glaucoma medication and treatment are a key factor that can hinder the rate of growth in the global glaucoma therapy market.

Global Glaucoma Therapeutics Market: Disease Indication

The global market for glaucoma treatment is classified in terms of disease classification into open-angle glaucoma, angle-closure glaucoma, and others (congenital glaucoma, secondary glaucoma, etc.). Open-angle glaucoma is the highly prevalent sign of disease among all forms of glaucoma and is expected to lead the industry in the coming years. Besides, increasing demand by pharmaceutical companies for prescription drugs and strategic alliances for the need for new medicines driving the demand for Open-Angle glaucoma market in the category with a lucrative growth rate for the 2020-2026 forecast.

Global Glaucoma Therapeutics Market: Drug Class

The glaucoma therapy market segmented into analogs of prostaglandin, beta-blockers, alpha agonists, and carbonic anhydrase inhibitors based on drug class. The highest market share in the Prostaglandin Analogues category by 2026. Prostaglandins have changed the face of the care scenario for glaucoma and are used as first-line glaucoma therapy. The prostaglandin analogs segment represented a significant market share in 2019 and is expected to remain dominant over the 2020-2026 forecast period. Attributable to their efficacy as opposed to other treatments in reducing the 10P and fewer side effects. The category of prostaglandin analogs is further categorized into latanoprost, bimatoprost, travoprost, and others, where latanoprost captured the highest revenue share due to its substantial penetration in highly prevalent and emerging economies.

Global Glaucoma Therapeutics Market: Regional Insights

Global Glaucoma Therapeutics market segregated into five regions, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the glaucoma therapy segment due to the large healthcare system. Europe & Asia-Pacific, led by North America, will contribute significant growth in the global glaucoma market in the coming years. The favorable reimbursement scenario is responsible for the high growth of the glaucoma therapy market in Western Europe. Asia-Pacific area has also shown significant growth in the demand for glaucoma therapy due to the increase of the geriatric population. In the Asia-Pacific region over the forecast period, China and India are predicted to be the leading market for glaucoma therapy. Latin America and the Middle East and Africa are the least-profitable markets for glaucoma therapy due to less patient awareness of glaucoma.

Glaucoma Therapeutics: Competitive Landscape

The major market players in Glaucoma Therapeutics are Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries, Aerie Pharmaceutical, Pfizer Inc., Inotek Pharmaceuticals, Akorn Inc., Santen, and Other Prominent Players.

The objective of the Study:

To analyze and forecast the global market size of the Glaucoma Therapeutics.

Analyzing careful market segmentation and estimating value-based market size through region-based segmentation.

The global GlaucomaTherapeutics is divided into five regions: North America, Europe,

Asia-Pacific, Middle East, South America, and their leading countries.

To outline, categorize, and forecast the global AI in the agricultural market based on Disease Indication, Drug Class, and Distribution Channel with the region.

To examine competitive developments in the global Glaucoma market, such as technological advancement, services, and regulatory framework.

To emphasize the impact study of market dynamics variables such as users, constraints, opportunities, and challenges.

Profiling key players strategically and analyzing their market shares comprehensively, together with detailing the competitive environment for market leaders.

Scope of the Report:

 

Attribute Details
Years Considered Historical data – 2016-2019
Base Year – 2019
Forecast – 2020 – 2026
Facts Covered Revenue in USD Million/Billion
Market Coverage U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia 
Product/Service Segmentation By Disease Indication, Drug Class, and Distribution Channel
Key Players Merck & Co., Inc., Novartis AG, Allergan plc, Bausch & Lomb Incorporated, Teva Pharmaceutical Industries, Aerie Pharmaceutical, Pfizer Inc., Inotek Pharmaceuticals, Akorn Inc., Santen, and Other Prominent Players

 

By Disease Indication

·         Open-Angle Glaucoma

·         Angle Closure Glaucoma

·         Others

By Drug Class

·         Beta-Blockers

·         Prostaglandin Analogues

o    Latanoprost

o    Bimatoprost

o    Travoprost

o    Others

·         Alpha Adrenergic Agonists

·         Carbonic Anhydrase Inhibitors

·         Combination Drugs

·         Others

By Distribution Channel

·         Hospital Pharmacy

·         Retail Pharmacy

·         Online Pharmacy

By Region: 

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East & Africa

Business Questions Answer by the Report

How will the market drivers, restraints, and opportunities affect the market dynamics?

What will be the market size in terms of value and volume and market statistics with a detailed classification?

Which segment dominates the market or region, and one will be the fastest-growing, and why?

A comprehensive survey of the competitive landscape and the market participant players

Analysis of strategy adopted by the key player and their impact on other players.

Customization Scope for the Client

Client satisfaction is our first and last priority, and that’s why BlueWeave Consulting offers customization according to Company’s specific needs. The following customization options are available for the report:

Additional Company Information

With five additional company detail analysis

Additional country analysis

Detailed segment analysis

1.    Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary & Secondary Sources

2.2. Quantitative Research

2.2.1.   Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4. Breakdown of Primary Research Respondents

2.5. Market Size Estimation

2.6. Assumption for The Study

2.7. Market Breakdown & Data Triangulation

3.    Executive Summary

4.    Global Glaucoma Therapeutics Insights

4.1. DROC Analysis

4.1.1.   Growth Drivers

4.1.2.   Restraints

4.1.3.   Opportunities

4.1.4.   Challenges

4.2. Technological Landscape

4.3. Regulatory Framework

4.4. Company Market Share Analysis, 2019

4.5. Porter’s Five forces analysis

4.5.1.   Bargaining Power of Suppliers

4.5.2.   Bargaining Power of Buyers

4.5.3.   Threat of New Entrants

4.5.4.   Threat of Substitutes

4.5.5.   Intensity of Rivalry

5.    Global Glaucoma Therapeutics Market Overview

5.1. Market Size & Forecast by Value, 2016-2026

5.1.1.   By Value (USD Million)

5.2. Market Share & Forecast 2016-2026

5.2.1.   By Disease Indication

5.2.1.1.       Open-Angle Glaucoma

5.2.1.2.       Angle Closure Glaucoma

5.2.1.3.       Others

5.2.2.   By Drug Class

5.2.2.1.       Beta-Blockers

5.2.2.2.       Prostaglandin Analogues

5.2.2.3.       Alpha Adrenergic Agonists

5.2.2.4.       Carbonic Anhydrase Inhibitors

5.2.2.5.       Combination Drugs

5.2.2.6.       Others

5.2.3.   By Distribution Channel

5.2.3.1.       Hospital Pharmacy

5.2.3.2.       Retail Pharmacy

5.2.3.3.       Online Pharmacy

5.2.4.   By Region

5.2.4.1.       North America

5.2.4.2.       Europe

5.2.4.3.       Asia Pacific

5.2.4.4.       Latin America

5.2.4.5.       Middle East & Africa

6.    North America Glaucoma Therapeutics Market

6.1. Market Size & Forecast by Value, 2016-2026

6.1.1.   By Value (USD Million)

6.2. Market Share & Forecast 2016-2026

6.2.1.   By Disease Indication

6.2.2.   By Drug Class

6.2.3.   By Distribution Channel

6.2.4.   By Country

6.2.4.1.       U.S

6.2.4.2.       Canada

7.    Europe Glaucoma Therapeutics Market

7.1. Market Size & Forecast by Value, 2016-2026

7.1.1.   By Value (USD Million)

7.2. Market Share & Forecast 2016-2026

7.2.1.   By Disease Indication

7.2.2.   By Drug Class

7.2.3.   By Distribution Channel

7.2.4.   By Country

7.2.4.1.       Germany

7.2.4.2.       U.K

7.2.4.3.       France

7.2.4.4.       Italy

7.2.4.5.       Spain

7.2.4.6.       Rest of Europe

8.    Asia Pacific Glaucoma Therapeutics Market

8.1. Market Size & Forecast by Value, 2016-2026

8.1.1.   By Value (USD Million)

8.2. Market Share & Forecast 2016-2026

8.2.1.   By Disease Indication

8.2.2.   By Drug Class

8.2.3.   By Distribution Channel

8.2.4.   By Country

8.2.4.1.       China

8.2.4.2.       India

8.2.4.3.       Japan

8.2.4.4.       South Korea

8.2.4.5.       Rest of Asia Pacific

9.    Latin America Glaucoma Therapeutics Market

9.1. Market Size & Forecast by Value, 2016-2026

9.1.1.   By Value (USD Million)

9.2. Market Share & Forecast 2016-2026

9.2.1.   By Disease Indication

9.2.2.   By Drug Class

9.2.3.   By Distribution Channel

9.2.4.   By Country

9.2.4.1.       Brazil

9.2.4.2.       Mexico

9.2.4.3.       Argentina

9.2.4.4.       Rest of Latin America

10.Middle East & Africa Glaucoma Therapeutics Market

10.1.             Market Size & Forecast by Value, 2016-2026

10.1.1.                By Value (USD Million)

10.2.             Market Share & Forecast 2016-2026

10.2.1.                By Disease Indication

10.2.2.                By Drug Class

10.2.3.                By Distribution Channel

10.2.4.                By Country

10.2.4.1.    Saudi Arabia

10.2.4.2.    UAE

10.2.4.3.    South Africa

10.2.4.4.    Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

11.1.             The Linde Group

11.2.             Air Liquide S.A.

11.3.             Illinois Tool Works Inc.

11.4.             Colfax Corporation

11.5.             Lincoln Electric Holdings Inc.

11.6.             Messer Group

11.7.             African Oxygen Limited

11.8.             GCE Holding AB

11.9.             Koike Aronson, Inc.

11.10.          Fronius International GmbH

11.11.          Matheson Tri-Gas, Inc.

11.12.          Bug-O Systems Inc.

11.13.          Gentec (Shanghai) Corporation

11.14.          British Oxygen Company

11.15.          Müller Opladen

11.16.          Cavagna Group

11.17.          Rotarex

11.18.          Other Prominent Players

 

List of Figures:

Fig: Global Glaucoma Therapeutics Segmentation

Fig: Company Market Share Analysis, 2019

Fig: Global Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Global Glaucoma Therapeutics Market Share, By Region, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: North America Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: North America Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Europe Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Europe Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Asia-Pacific Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Latin America Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Glaucoma Therapeutics Market Size, By Value (USD Million), 2016-2026

Fig: Middle-East & Africa Glaucoma Therapeutics Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Disease Indication, By Value, 2016-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Drug Class, By Value, 2016-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Middle East & Africa Glaucoma Therapeutics Market Share, By Country, By Value, 2016-2026

 

List of Tables:

Table: Global Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Global Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Global Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Global Glaucoma Therapeutics Market Size, By Region, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: North America Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Europe Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Asia-Pacific Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Latin America Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Disease Indication, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Drug Class, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Distribution Channel, By Value, 2016-2026

Table: Middle East & Africa Glaucoma Therapeutics Market Size, By Country, By Value, 2016-2026

Table: Merck & Co., Inc. Financial Analysis

Table: Novartis AGFinancial Analysis

Table: Allergan plc Financial Analysis

Table: Bausch & Lomb IncorporatedFinancial Analysis

Table: Teva Pharmaceutical IndustryFinancial Analysis

Table: Aerie PharmaceuticalFinancial Analysis

Table: Pfizer Inc.Financial Analysis

Table: Inotek PharmaceuticalsFinancial Analysis

 

*Financial Information of non-listed companies will be provided as per the availability

 

**The segmentation and the companies are subjected to modification based on the in-depth secondary for the final deliverable.

Market Segmentation

By Disease Indication

· Open-Angle Glaucoma

· Angle Closure Glaucoma

· Others

By Drug Class

· Beta-Blockers

· Prostaglandin Analogues

o Latanoprost

o Bimatoprost

o Travoprost

o Others

· Alpha Adrenergic Agonists

· Carbonic Anhydrase Inhibitors

· Combination Drugs

· Others

By Distribution Channel

· Hospital Pharmacy

· Retail Pharmacy

· Online Pharmacy

By Region:

· North America

· Europe

· Asia Pacific

· Latin America

· Middle East & Africa

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.